Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

293
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
293
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

96
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
96
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

115
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
115
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.8K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

117
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
117
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

250
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
250

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Traumatic Brain Injury in an Elite Adolescent Soccer Goalkeeper: A Case Report.

Cureus·2026
Same author

A temporal-spectral dual-stream anti-noise bearing fault diagnosis model based on adaptive mode decomposition.

Scientific reports·2026
Same author

Virtual Surgical Planning for Reconstruction of Mandibular Osteoradionecrosis: A Comparative Study on Its Safety and Outcomes.

Head & neck·2026
Same author

Hybrid versus cemented implants for total hip replacement: a randomised feasibility study with embedded qualitative research.

BMC musculoskeletal disorders·2026
Same author

RNA-Based Biomarkers for Diagnostic Discrimination of Ischemic and Hemorrhagic Stroke: A Systematic Review.

Journal of clinical medicine·2026
Same author

Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service.

British journal of cancer·2026

Related Experiment Video

Updated: Nov 20, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.3K

Tenecteplase for Acute Ischemic Stroke Treatment.

Alison E Baird1, Richard Jackson1, Weijun Jin1

  • 1SUNY Downstate Medical Center, Brooklyn, New York.

Seminars in Neurology
|January 20, 2021
PubMed
Summary
This summary is machine-generated.

Tenecteplase (TNK) shows promise as an alternative to alteplase for acute ischemic stroke treatment. Clinical trials suggest TNK offers comparable efficacy and safety, with potential advantages in administration and specific stroke types.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.2K
Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
09:52

Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide

Published on: January 15, 2017

17.5K

Related Experiment Videos

Last Updated: Nov 20, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.3K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.2K
Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
09:52

Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide

Published on: January 15, 2017

17.5K

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Intravenous recombinant tissue plasminogen activator (rt-PA) is the standard thrombolytic for acute ischemic stroke.
  • Tenecteplase (TNK) is an emerging thrombolytic agent with improved properties over rt-PA.
  • TNK demonstrates greater fibrin specificity, slower clearance, and increased resistance to plasminogen activator inhibitor-1.

Purpose of the Study:

  • To evaluate Tenecteplase (TNK) as a potential replacement for alteplase (rt-PA) in acute ischemic stroke treatment.
  • To compare the efficacy and safety of TNK versus rt-PA.
  • To explore TNK's potential for extended applications like wake-up stroke.

Main Methods:

  • Review of clinical trials comparing TNK and rt-PA for acute ischemic stroke.
  • Analysis of pharmacokinetic and pharmacodynamic properties of TNK and rt-PA.
  • Ongoing Phase 3 studies comparing rt-PA with TNK for acute ischemic stroke within 4.5 hours.

Main Results:

  • TNK has shown similar efficacy and safety profiles to rt-PA in several clinical trials.
  • TNK may offer superior reperfusion for large vessel occlusions, though clinical outcomes are pending.
  • Easier bolus-only administration makes TNK a practical alternative.

Conclusions:

  • TNK is a promising alternative to rt-PA for acute ischemic stroke.
  • Further research is ongoing to confirm TNK's non-inferiority and explore extended indications.
  • TNK has the potential for improved lysis with fewer hemorrhagic complications.